The effect of orlistat and weight loss diet on plasma ghrelin and obestatin

Abstract

Background:The objective of this study was to evaluate the effect of weight loss with hypocaloric diet and orlistat treatment in addition to hypocaloric diet on gut-derived hormones ghrelin and obestatin.Materials and Methods:A total of 52, euglycemic and euthyroid, obese female patients were involved in the study. The patients were assigned to two groups: Group 1 (n = 26) received hypocaloric diet alone and Group 2 (n = 26) received orlistat in addition to hypocaloric diet for 12 weeks. Anthropometric measurements, serum lipid, insulin levels, and obestatin and ghrelin values were assessed at the beginning of the study and after 12 weeks of therapy.Results:Baseline clinical characteristics and laboratory parameters including serum ghrelin and obestatin concentrations and ghrelin/obestatin ratio were similar between the two groups. After 12 weeks, mean change in BMI, fat mass, and fat-free mass (FFM) were −1.97 ± 1.56 kg/m2 (P = 0.003), −2.63% ±2.11% (P = 0.003), and −1.06 ± 0.82 kg (P = 0.003), respectively, in Group 1. In Group 2, mean change in BMI was −2.11 ± 1.24 kg/m2 (P = 0.001), fat mass was −3.09% ±2.28% (P = 0.002), and FFM was −1.26 ± 0.54 kg (P = 0.001). However, fasting glucose, lipid, and insulin levels did not change in Group 1. Furthermore, except serum high-density lipoprotein cholesterol and triglyceride levels, no significant change was observed in Group 2. Although serum ghrelin and obestatin concentrations increased significantly in both groups (Group 1: pGhrelin: 0.047, pobestatin: 0.001 and Group 2: pGhrelin: 0.028, pobestatin: 0.006), ghrelin/obestatin ratio did not change significantly. When the changes in anthropometric assessments and laboratory parameters were compared, no significant difference was observed between the two groups. Furthermore, no correlation was observed between ghrelin or obestatin and any other hormonal and metabolic parameters.Conclusion:Weight loss with diet and diet plus orlistat is both associated with increased ghrelin and obestatin concentrations.

Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation

“…Our results are in accordance with previous reported studies, which demonstrated no changes in the food intake after 12-week administration of orlistat in obese male rats [34,62]. However, other related studies reported increased appetite after orlistat consumption as shown by increased level of serum ghrelin (gut-derived hormone) in obese women (who received 120 mg orlistat, 3 times/day for 12 weeks) [63], reduced levels of plasma cholecystokinin (CCK) (for inducing fullness and reducing hunger), peptide YY (PYY) and glucagon-like peptide-1-(7-36)-amide (GLP-1) in healthy individuals (received single dose of 120 mg orlistat) [64]. These inconsistencies might be due to the differences in types of subject and doses of orlistat used, as well as the durations of the studies.…”

Moderate Weight Loss Modifies Leptin and Ghrelin Synthesis Rhythms but Not the Subjective Sensations of Appetite in Obesity Patients

“…Previous reports have shown conflicting results in this regard, indicating the lack of effect of diet-induced weight loss on the plasma ghrelin levels [44,45]. Pamuk et al observed a slight increase in ghrelin levels after an orlistat-induced weight loss [46]. However, as these previous works only evaluated one specific ghrelin measurement, comparisons should be made with caution.…”

Efecto de la dieta cetogénica baja en calorías sobre la composición corporal en adultos con sobrepeso y obesidad: revisión sistemática y metaanálisis

“…La obesidad representa un problema de salud pública a nivel mundial debido a su asociación con enfermedades crónicas no transmisibles y reducción de la calidad y expectativa de vida (1,2) . La estrategia terapéutica reconocida es el tratamiento médico-nutricional, que incluye dietoterapia, fármacos y la cirugía bariátrica (3)(4)(5)(6)(7) . El tratamiento médico-nutricional, bajo un enfoque multidisciplinario, busca lograr un estilo de vida saludable en el paciente con obesidad.…”